This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Are Bullish on Top Healthcare Stocks: Autolus Therapeutics (AUTL), Wuxi Biologics (Cayman) (WXIBF)

Tipranks - Tipranks - Wed Jun 3, 7:24PM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Autolus Therapeutics (AUTL), Wuxi Biologics (Cayman) (WXIBF) and Tarsus Pharmaceuticals (TARS) with bullish sentiments.

Claim 55% Off TipRanks

Autolus Therapeutics (AUTL)

William Blair analyst Matt Phipps maintained a Buy rating on Autolus Therapeutics yesterday. The company’s shares closed last Tuesday at $1.75, close to its 52-week low of $1.56.

According to TipRanks.com, Phipps is a 4-star analyst with an average return of 5.2% and a 45.0% success rate. Phipps covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Janux Therapeutics Inc, and Compass Therapeutics. ;'>

Autolus Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $8.08.

See Insiders’ Hot Stocks on TipRanks >>

Wuxi Biologics (Cayman) (WXIBF)

In a report issued on June 1, Laurence Tam from Morgan Stanley maintained a Buy rating on Wuxi Biologics (Cayman), with a price target of HK$50.00. The company’s shares closed last Tuesday at $4.18.

According to TipRanks.com, Tam is ranked #10105 out of 12287 analysts.

Currently, the analyst consensus on Wuxi Biologics (Cayman) is a Strong Buy with an average price target of $5.78.

Tarsus Pharmaceuticals (TARS)

In a report released today, Lachlan Hanbury Brown from William Blair maintained a Buy rating on Tarsus Pharmaceuticals. The company’s shares closed last Tuesday at $57.41.

According to TipRanks.com, Brown is a 3-star analyst with an average return of 2.7% and a 40.7% success rate. Brown covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, Kalaris Therapeutics, and ARS Pharmaceuticals. ;'>

Tarsus Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $95.17, which is a 63.5% upside from current levels. In a report issued on May 26, H.C. Wainwright also maintained a Buy rating on the stock with a $88.00 price target.

Read More on AUTL:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).